$51.64▾ 1.54%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-369.58MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+1041.4%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
✦ The read
CRISPR Therapeutics AG - Common Shares is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$-4.74
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-3368.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$13.39M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days5 articles
2 bullish3 neutral0 bearish
3 Stocks With the Most Upside by the End of 2026
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Vertex’s Crinetics Deal Balances Growth with Integration Risk
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.